An observational study in Endometrial Cancer, Endometrial Intraepithelial Neoplasia and Fertility-sparing Surgery, sponsored by Region Stockholm. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by Region Stockholm · Observational
We will investigate the safety and efficiency of fertility-sapring treatment in ypung women witg endometrial cancer and endometrial intraepithelial hyperplasia
A multi-center prospective study on the oncological and reproductive outcomes and quality of life in young woman after fertility-sparing treatment of endometrial cancer and endometrial intraepithelial hyperplasia
1,425 studies on the registry are indexed under Endometrial Neoplasms; 473 are open to participants now.
This study's planned enrollment of 100 is below the median of 179 across 331 observational studies indexed under Endometrial Neoplasms.
Browse Endometrial Neoplasms studies →Region Stockholm is the lead sponsor of 121 studies on the registry; 69 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All women in Sweden
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Relaps of endometrial cancer or EIN after fertility-sparing treatment
Relaps of endometrial cancer or EIN after fertility-sparing treatment
Time frame: from enrollment to 2 years after fertility-sparing treatment
Live birth rate in women that has been treated with fertility-sparing treatment for EC or EIN
Live birth rate in women that has been treated with fertility-sparing treatment for EC or EIN
Time frame: From start of study to 2 years after fertility-sparing treatment
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Jan 2028, 36 months later.
Of 130 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 105 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 206. This study's planned 36 months is below that.
Counting every sponsor, half of 150 studies reached it within 105 months; a quarter within 32 and three quarters within 207.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.